The global late-stage chronic kidney disease therapeutics market is experiencing remarkable growth, fueled by a rising global disease burden and continuous innovation in treatment options. According to recent market research, the late-stage CKD therapeutics market was valued at approximately USD 4.7 billion in 2019 and is projected to exceed USD 11.1 billion by 2027, reflecting a Compound Annual Growth Rate (CAGR) of around 11.6% from 2022 to 2032.
Rising Global Disease Burden Creates Market Demand:
Chronic kidney disease has emerged as a critical public health concern, with a significant rise in prevalence worldwide. A Lancet report estimates that around 700 million people were affected by CKD in 2017, with projections indicating an even sharper increase in the coming years. This surge in cases, particularly in late-stage CKD, is driving an escalating demand for effective therapeutics to manage the condition.
As factors such as diabetes mellitus, hypertension, obesity, and aging contribute to the rising prevalence of CKD, the healthcare industry is under increasing pressure to address the needs of this growing patient population. This presents a significant opportunity for therapeutic innovation and market expansion.
Innovation and Expanding Awareness Fuel Market Growth:
The late-stage CKD therapeutics market is further bolstered by the introduction of novel and advanced treatment options that offer improved patient outcomes. These innovative therapies not only address existing gaps in patient care but also offer hope for individuals battling this life-threatening disease. Additionally, growing awareness among both healthcare professionals and patients about the benefits of these treatments is accelerating market dynamics.
Favorable Reimbursement Policies and Limited Dialysis Access Create Opportunities:
Government bodies and healthcare institutions are playing a key role in supporting the market through favorable reimbursement policies for CKD treatments. This supportive environment is facilitating the broader adoption of new therapeutic options. Furthermore, limited access to renal replacement therapy (RRT) and dialysis, particularly in developing countries, creates an urgent need for alternative late-stage CKD treatment options. This is driving the demand for advanced therapeutics as viable solutions.
Accelerated Market Demand: Find Comprehensive Insights and Trends in Our Full Report!
A Promising Future for Late-Stage CKD Therapeutics:
The convergence of rising disease prevalence, continuous innovation in treatment options, growing patient and healthcare awareness, and supportive healthcare policies is positioning the late-stage CKD therapeutics market for robust growth. With ongoing research and development paving the way for more effective and accessible treatments, the future of CKD care looks brighter than ever.
As the global healthcare and pharmaceutical industries continue to invest in innovative solutions, the market for late-stage CKD therapeutics is set to thrive, improving patient outcomes and quality of life for millions worldwide.
Key Companies Profiled:
- Amgen
- Deltanoid
- AbbVie
- Sanofi
- Ardelyx
- AstraZeneca
- Kyowa Hakko Kirin
- Genzyme, Keryx
- Spectrum
- Mitsubishi Tanabe
- OPKO Health
- Relypsa
- Shield Therapeutics
- Shire
- Vifor
- ZS Pharma
Key Segments Profiled in the Late Stage Chronic Kidney Disease Therapeutics Industry Survey:
By Product Type:
- Calcimimetics
- Sensipar (cinacalcet hydrochloride)
- Vitamin D Sterols
- Nutritional/Native Vitam:in D
- Vitamin D Receptor Agonists
- Phosphate Binders
- Calcium-Based Phosphate Binders
- Aluminum-Containing Phosphate Binders
- Magnesium-Containing Phosphate Binders
- Renvela/Renagel
- Fosrenol (lanthanum carbonate)
- Velphoro (sucroferric oxyhydroxide)
- Auryxia (ferric citrate)
- Potassium Binders
- Resins
- Veltassa (patiromer sorbitex calcium)
By Indication:
- Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
- Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
- Late Stage Chronic Kidney Disease Induced Hyperkalemia
By End Users:
- Hospital Pharmacy
- Retail Pharmacy
- Mail Order Pharmacy
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
- Japan
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
